Temperature-Stable Messenger Ribonucleic Acid (mRNA) Vial Market Report 2026

The temperature-stable messenger ribonucleic acid (mrna) vial market size has grown rapidly in recent years. It will grow from $2.01 billion in 2025 to $2.28 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to expansion of mrna vaccine research, increased investment in lipid nanoparticle technologies, growth in global immunization programs, reliance on cold-chain logistics limitations, early adoption of stabilized mrna delivery systems.

The temperature-stable messenger ribonucleic acid (mrna) vial market size is expected to see rapid growth in the next few years. It will grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to increasing demand for next-generation mrna therapeutics, rising focus on global vaccine accessibility, expansion of decentralized healthcare delivery, growing investments in temperature-stable biologics, increased regulatory approvals for mrna-based products. Major trends in the forecast period include increasing development of thermostable mrna formulations, rising adoption of lyophilized mrna vials, growing demand for cold-chain independent storage solutions, expansion of global mrna distribution programs, enhanced focus on packaging integrity and stability.

The growing involvement in global vaccination is expected to drive the expansion of the temperature-stable messenger ribonucleic acid (mRNA) vial market going forward. A vaccine is a substance developed to stimulate the body’s immune system, helping it build protection against specific diseases. The increase in global vaccine participation is fueled by international cooperation, as coordinated efforts among countries ensure broader access and fair distribution of vaccines. Temperature-stable mRNA vials facilitate global vaccination by allowing easier storage, transport, and distribution across various regions without depending on complex cold chain systems, thereby promoting wider accessibility and consistent immunization coverage worldwide. For example, in October 2025, according to Gavi, a US-based international organization providing vaccines to children in developing countries, DTP3 vaccine coverage in Gavi-supported lower-income countries rose to 82%, up from 80% in 2023, approaching pre-pandemic levels. Consequently, the rising participation in global vaccination is driving the growth of the temperature-stable messenger ribonucleic acid (mRNA) vial market.

Major companies operating in the temperature-stable messenger ribonucleic acid (mRNA) vial market are concentrating on developing innovative strategies, such as technology transfer models, to boost manufacturing efficiency, expand global production capacity, and enhance accessibility of vaccines in low- and middle-income countries. Technology transfer models involve processes for sharing knowledge, expertise, and manufacturing techniques from one organization to another to facilitate local production and broader distribution. For example, in January 2024, SCHOTT Pharma, a Germany-based pharmaceutical packaging company, introduced the EVERIC freeze vials. EVERIC freeze vials can withstand temperatures as low as -80°C, making them suitable for vaccines and drugs such as mRNA and gene therapy treatments used for infectious diseases, cancer, and central nervous system disorders. Their strength-optimized design minimizes the risk of breakage, preventing loss of life-saving medications and expensive downtimes.

In February 2023, 20Med Equipment Solutions Private Limited, a Netherlands-based company providing digital transformation services and a B2B marketplace for healthcare businesses, partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop RNA and DNA vaccines and therapeutics. Through this partnership, CEPI and 20Med aim to advance bio-responsive nanoparticle technology to eliminate the need for frozen storage of mRNA vaccines and enhance global vaccine accessibility. The Coalition for Epidemic Preparedness Innovations (CEPI), a Norway-based organization, supports innovations such as temperature-stable mRNA vials to improve vaccine storage, distribution, and accessibility worldwide.

Major companies operating in the temperature-stable messenger ribonucleic acid (mrna) vial market are Arcturus Therapeutics Holdings Inc., CureVac AG, Sanofi S.A., Lonza Group AG, Gerresheimer AG, Stevanato Group, Schott AG, CSafe Global, Gennova Biopharmaceuticals Ltd., TTP Group, Peli BioThermal LLC, SiO2 Materials Science, Shijiazhuang Xinfuda Medical Packaging, Vaxess Technologies, Ethris, Lyophilization Techniques, 20Med Therapeutics BV, EnsiliTech, HDT Bio Corp., Emervax.

North America was the largest region in the temperature-stable messenger ribonucleic acid (mRNA) vial market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the temperature-stable messenger ribonucleic acid (mrna) vial market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the temperature-stable messenger ribonucleic acid (mrna) vial market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the temperature-stable mRNA vial market by increasing costs of imported glass vials, specialty polymers, lipid nanoparticle materials, lyophilization equipment, and advanced packaging technologies. Pharmaceutical supply chains in North America and Europe are most affected due to reliance on imported vial components and formulation materials, while Asia-Pacific faces cost pressure on manufacturing and export of stabilized mRNA products. These tariffs are increasing production costs and influencing pricing strategies. However, they are also encouraging local vial manufacturing, regional formulation capacity expansion, and innovation in alternative stabilization and packaging solutions.

The temperature-stable messenger ribonucleic acid (mrna) vial market research report is one of a series of new reports that provides temperature-stable messenger ribonucleic acid (mrna) vial market statistics, including temperature-stable messenger ribonucleic acid (mrna) vial industry global market size, regional shares, competitors with a temperature-stable messenger ribonucleic acid (mrna) vial market share, detailed temperature-stable messenger ribonucleic acid (mrna) vial market segments, market trends and opportunities, and any further data you may need to thrive in the temperature-stable messenger ribonucleic acid (mrna) vial industry. This temperature-stable messenger ribonucleic acid (mrna) vial market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A temperature-stable messenger ribonucleic acid (mRNA) vial is a specially engineered container that preserves the integrity and efficacy of mRNA formulations without the need for ultra-cold storage. It employs advanced stabilization technologies to safeguard the delicate mRNA molecules from degradation at elevated temperatures, enabling easier handling, broader distribution, and more dependable use of mRNA-based products.

The main product types of temperature-stable messenger ribonucleic acid (mRNA) vials include lipid nanoparticle formulations, polymer-based formulations, lyophilized messenger ribonucleic acid (mRNA) vials, and others. Lipid nanoparticle formulations are delivery systems that encapsulate and safeguard messenger RNA molecules for effective cellular uptake. They are distributed through direct sales, distributors, online sales, and others and are applied for vaccines, therapeutics, research, and more. They are used by various end users, including hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and others.

The temperature-stable messenger ribonucleic acid (mRNA) vial consists of sales of stoppers, seals, caps, labels, and packaging materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.